Overview
CHIROMIN-MET is a scientifically designed fixed-dose combination of Myo-Inositol 600 mg and Metformin Hydrochloride Sustained Release 500 mg, formulated to support the metabolic and reproductive aspects of Polycystic Ovary Syndrome (PCOS).
PCOS is a complex endocrine and metabolic condition commonly associated with insulin resistance, irregular menstrual cycles, ovulatory dysfunction and hormonal imbalance.
CHIROMIN-MET combines the insulin-sensitizing action of metformin with the metabolic and reproductive-supportive properties of myo-inositol, providing a complementary approach to PCOS management.
Composition
Each film-coated tablet contains:
Myo-Inositol IP — 600 mg
Metformin Hydrochloride IP (as Sustained Release) — 500 mg
Excipients — q.s.
Key Benefits
CHIROMIN-MET may help support:
Improved insulin sensitivity
Better metabolic control in women with PCOS
More regular menstrual cycles
Improved ovulatory function
Management of PCOS-associated metabolic dysfunction
Overall reproductive and metabolic health
A randomized Phase III clinical trial evaluating this specific myo-inositol 600 mg + metformin SR 500 mg combination reported greater improvement in insulin resistance and menstrual-cycle parameters compared with metformin alone.
Mechanism of Action
MYO-INOSITOL
Myo-inositol acts as an important intracellular signaling molecule involved in insulin signaling. By supporting insulin-mediated cellular responses, it may help address metabolic dysfunction associated with PCOS.
METFORMIN SR
Metformin improves insulin sensitivity and reduces hepatic glucose production. Its sustained-release formulation provides prolonged drug release and may improve gastrointestinal tolerability compared with immediate-release formulations.
THE COMBINATION
Myo-Inositol + Metformin SR
↓
Improved insulin sensitivity
↓
Better metabolic regulation
↓
Support for ovulatory function
↓
Improved menstrual-cycle regularity
↓
Comprehensive PCOS management
Indication
CHIROMIN-MET is indicated for the management of Polycystic Ovary Syndrome (PCOS), particularly where insulin resistance and menstrual/ovulatory disturbances are clinically relevant.
It should be used under the supervision of a qualified healthcare professional and alongside appropriate lifestyle measures.
Clinical Evidence
In a Phase III, double-blind, randomized multicenter clinical trial involving women with PCOS and insulin resistance, the combination of Metformin Hydrochloride SR 500 mg + Myo-Inositol 600 mg demonstrated a superior response compared with metformin alone for improvement in insulin resistance and menstrual-cycle disturbances over 24 weeks.
Who May Benefit?
CHIROMIN-MET may be considered by healthcare professionals for women with PCOS presenting with:
Insulin resistance
Irregular or infrequent menstrual cycles
Ovulatory dysfunction
Metabolic abnormalities associated with PCOS
Treatment should be individualized according to the patient’s clinical profile.
Suggested Lifestyle Support
PCOS management is most effective when pharmacological treatment is combined with appropriate lifestyle measures, including:
Balanced Nutrition + Regular Physical Activity + Weight Management Where Appropriate + Medical Follow-up
Important Safety Information
CHIROMIN-MET is a prescription medicine and should be taken only as directed by a healthcare professional.
Metformin may cause gastrointestinal adverse effects such as nausea, diarrhea, abdominal discomfort or loss of appetite, particularly during initiation. Patients should follow their physician’s instructions regarding dosing and administration.
Long-term metformin therapy may be associated with reduced vitamin B12 levels; appropriate clinical monitoring may be considered when indicated.
Patients should inform their healthcare professional about kidney disease, liver disease, pregnancy, breastfeeding or other medicines they are taking.
Disclaimer
The information provided on this page is intended for healthcare professionals and general educational purposes. It is not a substitute for professional medical advice, diagnosis or treatment.
CHIROMIN-MET should be used under the supervision of a qualified healthcare professional.
CHIROMIN-MET
Myo-Inositol 600 mg + Metformin Hydrochloride SR 500 mg
Supporting Metabolic Balance. Supporting PCOS Management.